EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa

Glenn J Rapsinski iD, Alecia B Rokes, Daria Van Tyne iD, Vaughn S Cooper iD

Microbiology Spectrum · 04.03.2025 · 13 (3)

DOI: 10.1128/spectrum.02312-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 04.03.2025. Verfasst von Glenn J Rapsinski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Anti-Bacterial Agents, Pseudomonas Infections, Drug Resistance, Multiple, Bacterial. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identifying resistance mechanisms to novel antimicrobials informs treatment strategies during infection and antimicrobial development. Studying resistance that develops during the treatment of an infection can provide the most clinically relevant mutations conferring resistance, but cross-sectional studies frequently identify multiple candidate resistance mutations without resolving the driver mutation. We performed whole-genome sequencing of longitudinal Pseudomonas aeruginosa from a patient whose P. aeruginosa developed imipenem/cilastatin/relebactam and ceftolozane/tazobactam resistance during ceftazidime/avibactam treatment. This analysis determined new mutations that arose in isolates resistant to both imipenem/cilastatin/relebactam and ceftolozane/tazobactam. Mutations in penicillin-binding protein 3 ftsI, the MexAB-OprM repressor nalD , and a virulence regulator pvdS were found in resistant isolates. Importantly, drug efflux was not increased in the resistant isolate compared to the most closely related susceptible isolates. We conclude that mutations in peptidoglycan synthesis genes can alter the efficacy of multiple antimicrobials. IMPORTANCE Antibiotic resistance is a significant challenge for physicians trying to treat infections. The development of novel antibiotics to treat resistant infections has not been prioritized for decades, limiting treatment options for infections caused by many high-priority pathogens. Cross-resistance, when one mutation provides resistance to multiple antibiotics, is most problematic. Mutations that cause cross-resistance need to be considered when developing new antibiotics to guide developers toward drugs with different targets, and thus a better likelihood of efficacy. This work was undertaken to determine the mutation that caused resistance to three antibiotics for highly resistant Pseudomonas aeruginosa infection treatment while the bacteria were exposed to only one of these agents. The findings provide evidence that drug developers should endeavor to find effective antibiotics with new targets and that medical providers should utilize medications with different mechanisms of action in bacteria that have become resistant to even one of these three agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaAnti-Bacterial AgentsPseudomonas InfectionsDrug Resistance, Multiple, BacterialAzabicyclo CompoundsCeftazidimeTazobactamCephalosporinsDrug CombinationsHumansImipenemMutationMicrobial Sensitivity TestsWhole Genome SequencingBacterial ProteinsCilastatinCilastatin, Imipenem Drug Combination

Stichwörter der Autor:innen

Pseudomonas aeruginosaantibiotic resistancedrug resistance evolution

Substanzen

Azabicyclo CompoundsAnti-Bacterial AgentsCeftazidimeTazobactamCephalosporinsDrug Combinationsavibactam, ceftazidime drug combinationceftolozane, tazobactam drug combinationImipenemBacterial Proteins

Autor:innen und Institutionen

  • Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Division of Infectious Disease, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Center for Evolutionary Biology and Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Glenn J Rapsinski, Daria Van Tyne, Vaughn S Cooper

Förderung

  • HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • NICHD NIH HHS
  • University of Pittsburgh School of Medicine Department of Medicine
  • NIAID NIH HHS
  • UPMC Children's Hospital of Pittsburgh CHP Scholars

Zitieren

APA

Rapsinski, G. J., Rokes, A. B., Van Tyne, D., & Cooper, V. S. (2025). Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa. Microbiology Spectrum, 13(3). https://doi.org/10.1128/spectrum.02312-24

Vancouver

Rapsinski GJ, Rokes AB, Van Tyne D, Cooper VS. Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa. Microbiology Spectrum. 2025;13(3). doi:10.1128/spectrum.02312-24

BibTeX
@article{Rapsinski2025,
  author = {Rapsinski, Glenn J and Rokes, Alecia B and Van Tyne, Daria and Cooper, Vaughn S},
  title = {Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa},
  journal = {Microbiology Spectrum},
  year = {2025},
  volume = {13},
  number = {3},
  doi = {10.1128/spectrum.02312-24}
}
Kostenlos starten →